Racial disparities in antibiotic prescription also influence treatment decisions.

People are born with sterile skin and then gain microbiota throughout their life. Lawrence J. Green, MD, FAAD, explains how this affects the skin barrier and ultimately plays a role in atopic dermatitis at the 2021 Fall Clinical Dermatology Conference.

ICYMI, some of this week’s featured content includes an exclusive interview about eczema, and articles on a new tralokinumab data, apremilast as a combination treatment, and more.

In a video onsite at Fall Clinical Dermatology Conference, Darrell S. Rigel, MD, MS, highlights, in his own words, the potential of GEP as an adjunct to biopsy in melanoma detection.

Lawrence Eichenfield, MD, provides the newest updates in pediatric patient care, with a special update on COVID-19 skin symptoms in children.

LEO Pharma releases the 16-week data regarding tralokinumab (Adtralza; LEO Pharma) as a treatment for adolescent patients aged 12 to 17 years.

Cantharidin 0.7% could be an emerging standard for molluscum treatment.

How can GEP be applied to melanoma diagnosis and treatment? Darrel Rigel, MD, MS, answers these questions and dives into the data at Fall Clinical Dermatology Conference 2021.

Neal Bhatia, MD, explores steroid alternatives in his presentation at the Fall Clinical Dermatology Conference.

Click here to answer this week's poll.

Case-based observations offered clinicians real-world guidance on distinguishing underlying malignancies in the Therapeutic Hotline session at Maui Derm NP+PA Fall 2021.

In a grand rounds presentation at the Maui Derm NP+PA Fall 2021 conference, Seemal Desai, MD, FAAD, Raegan Hunt, MD, PhD, Ted Rosen, MD, and Matthew J. Zirwas, MD, discussed some of their challenging cases.

Which is more worrisome, neonatal or infantile acne? An expert answered this question and more during Maui Derm NP+PA Fall 2021’s update on acne and rosacea.

In his presentation at Maui Derm NP+PA Fall 2021, Jerry Shapiro, MD, FAAD, shared his treatment protocols for lupus erythematosus, lichen planopilaris, folliculitis decalvans, and dissecting cellulitis.

Learning to identify some well-disguised drivers of eczema and contact dermatitis can speed patients toward clear or almost clear, according to a presentation at Maui Derm NP+PA Fall 2021.

Ted Rosen, MD, and Sheila Fallon Friedlander, MD, discuss infectious disease updates at the virtual Maui Derm NP+PA Fall 2021 conference.

In this presentation on rosacea from Maui Derm NP+PA Fall 2021, Julie Harper, MD, explains why combination therapy is more effective and how classifying rosacea patients by subtype can lead to suboptimal treatments.

Factors include extent of disease, the latest findings on agents’ efficacy, and even patient weight.

At Maui Derm NP+PA Fall 2021, George Martin, MD, discussed his opinion on best treatment options for SCC in situ and cutaneous SCC at high risk for metastasis along with BCC that require special considerations.

Patients with mild to moderate AD have a new topical treatment option, but physicians will need to prepare for some focused conversations about safety.